GlycoMimetics(GLYC) - 2025 Q4 - Annual Results

Financial Performance - Revenue for the full year 2025 was $10.8 million, a significant increase from no revenue in 2024, primarily due to a $20 million upfront payment from Kelun-Biotech for the CR-001 license[7] - General and administrative (G&A) expenses for the full year 2025 were $25.4 million, compared to $3.2 million for the period from inception to December 31, 2024, driven by increased personnel costs and professional services[10] - Net loss for Q4 2025 was $92.4 million, or $4.01 per share, compared to a net loss of $15.2 million, or $19.74 per share, in Q4 2024[11] - Total assets increased significantly to $240.293 million in December 31, 2025, compared to $35.617 million in December 31, 2024, representing a growth of 576%[20] - Cash reserves rose to $213.192 million from $34.766 million, indicating a substantial increase of 513% year-over-year[20] - Liabilities decreased to $37.281 million from $47.096 million, reflecting a reduction of approximately 21%[20] - Shareholders' equity improved to $203.012 million from a deficit of $11.479 million, marking a turnaround of over $214.491 million[20] Research and Development - Research and development (R&D) expenses for Q4 2025 were $95 million, up from $11.6 million in Q4 2024, reflecting ongoing development of CR-001 and CR-002[8] - Crescent is advancing the ASCEND Phase 1/2 clinical trial for CR-001, with initial data expected in Q1 2027, and plans to initiate three additional trials in 2026[2] - The company anticipates submitting an IND for CR-002 in mid-2026, with proof-of-concept data expected in the second half of 2027[8] - CR-003, an investigational ADC targeting integrin beta-6, received IND approval in January 2026, with a Phase 1/2 trial planned to start in Greater China in Q1 2026[8] Partnerships and Funding - Crescent Biopharma completed a $185 million private placement to support key clinical data readouts beginning in Q1 2027 and to provide a cash runway into 2028[5] - Crescent's partnership with Kelun-Biotech aims to develop and commercialize next-generation oncology therapeutics, including CR-001 and CR-003, across various markets[5] - As of December 31, 2025, Crescent had a cash position of $213.2 million, expected to fund operations into 2028[7]